Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
The Waitangi Tribunal releases an interim report urging the New Zealand Crown to halt work on the proposed Regulatory Standards Bill and to engage in "meaningful consultation" with Māori. Deputy Prime Minister Winston Peters, Regional Development Minister Shane Jones, Labour Party MP Ingrid Leary attend a reopening ceremony at Hillside Engineering. Pro-Palestine, transgender rights, pay equity and climate change protesters picket the event. 20 May: Foreign Minister Winston Peters joins 22 other foreign ministers and the European Union in calling on Israel to allow a full resumption of aid to the Gaza Strip. Two groups of protesters gather outside the New Zealand Parliament to call for the NZ Government to lower the bowel cancer screening age and oppose the suspension of three Te Pāti Māori MPs. The New Zealand Parliament votes to postpone a debate on the Privileges Committee's decision to suspend three Te Pāti Māori MPs until 5 June, allowing them to participate in an upcoming debate around the 2025 New Zealand budget. 22 May: Finance Minister Nicola Willis releases the 2025 New Zealand budget. The Wellington City Council votes to preserve the historic Begonia House and Khandallah Pool, while making cutbacks in transport infrastructure and renovations to Wellington Zoo. The Council also introduces parking fees for motorcycles in the Wellington CBD. 23 May – The New Zealand Geographic Board and Land Information Minister Chris Penk decline a proposal by the Kororāreka Marae Society to rename Russell to its Māori language name "Kororāreka".
== Other uses == Caldwell 8 (NGC 559), an open cluster in Cassiopeia Celestron, 8-inch (200 mm) a Schmidt-Cassegrain telescope C8 carbine, an assault rifle used by Canada and other NATO forces made by Diemaco/Colt Canada C8 Unemployment Indemnity (Shipwreck) Convention, 1920 Elbrus-8C, a Russian 28 Nanometre 8 core microprocessor An international standard paper size (57×81 mm), defined in ISO 216
For example, the energetics of the covalent bond to the serine molecule in chymotrypsin should be compared to the well-understood covalent bond to the nucleophile in the uncatalyzed solution reaction. A true proposal of a covalent catalysis (where the barrier is lower than the corresponding barrier in solution) would require, for example, a partial covalent bond to the transition state by an enzyme group (e.g., a very strong hydrogen bond), and such effects do not contribute significantly to catalysis.
== Typical technique == A sample is introduced, either manually or with an autosampler, into a sample loop of known volume. A buffered aqueous solution known as the mobile phase carries the sample from the loop onto a column that contains some form of stationary phase material. This is typically a resin or gel matrix consisting of agarose or cellulose beads with covalently bonded charged functional groups. Equilibration of the stationary phase is needed in order to obtain the desired charge of the column. If the column is not properly equilibrated the desired molecule may not bind strongly to the column. The target analytes (anions or cations) are retained on the stationary phase but can be eluted by increasing the concentration of a similarly charged species that displaces the analyte ions from the stationary phase. For example, in cation exchange chromatography, the positively charged analyte can be displaced by adding positively charged sodium ions. The analytes of interest must then be detected by some means, typically by conductivity or UV/visible light absorbance. Control an IC system usually requires a chromatography data system (CDS). In addition to IC systems, some of these CDSs can also control gas chromatography (GC) and HPLC.
Sources: en.wikipedia.org
Since 1971, SI defined the "amount of substance" as a separate dimension of measurement. Until 2019, the mole was defined as the amount of substance that has as many constituent particles as there are atoms in 12 grams of carbon-12, with the dalton defined as +1/12 of the mass of a carbon-12 atom. Thus, during that period, the numerical value of the molar mass of a substance expressed in g/mol was exactly equal to the numerical value of the average mass of an entity (atom, molecule, formula unit) of the substance expressed in daltons. Since 2019, the mole has been redefined in the SI as the amount of any substance containing exactly 6.02214076×1023 entities, fixing the numerical value of the Avogadro constant NA when expressed in the unit mol−1, but because the dalton is still defined in terms of the experimentally determined mass of a carbon-12 atom, the numerical equivalence between the molar mass of a substance and the average mass of an entity of the substance is now only approximate, but equality may still be assumed with high accuracy—(the relative discrepancy is only of order 10–9, i.e. within a part per billion).
Whitney Halberstram (Max Minghella) is the enigmatic co-founder and CFO of payment processing startup Tender, which he launches with college friend Jonah Atterbury. An American who claims to have grown up in poverty, Whitney frequently alters details about his background depending on his audience. He pivots Tender away from pornography and gambling clients toward banking, forcing Jonah out and installing himself as interim CEO. Whitney has a one-night stand with Harper and befriends Yasmin, who introduces him to Labour MP Jennifer Bevan for regulatory leverage in exchange for securing her husband Henry Muck a role at Tender. Whitney appoints Henry CEO to leverage his aristocratic connections and develops a sexual fixation on him. After learning Harper is shorting Tender and working with journalist James Dycker to investigate its African operations, Whitney and Yasmin move to discredit Dycker in print; Whitney then promotes Yasmin to head of communications. After Harper publicly reveals that Tender falsified profits in Africa, the company’s stock drops sharply. Whitney is shown to be under pressure from Russian intelligence interests using Tender to collect UK consumer data. He persuades EMEA CFO Tony Day not to act as a whistleblower and proposes a hostile takeover of Pierpoint to delay scrutiny from auditors, falsely claiming he already owns a stake. He travels to New York with Henry for Pierpoint’s AGM but later attempts to flee, having secured a fake Lithuanian passport and hired a Japanese jōhatsu firm to facilitate his disappearance.
== Controversy == The 2014 summary policy statement of the American Academy of Pediatrics (AAP) makes no specific mention of bottle feeding, but makes clear that "[b]reastfeeding and human milk are the normative standards for infant feeding and nutrition", and refers to decisions regarding the supply of infant nutrition as "a public health issue and not only a lifestyle choice… [g]iven the documented short- and long-term medical and neurodevelopmental advantages of breastfeeding". The AAP policy recommends breastfeeding exclusively for six months, continuing it with introduction of complementary foods, with an overall duration of "1 year or longer as mutually desired by mother and infant". The body of the policy statement notes and cites literature indicating that, in addition to the importance of mother's milk, the manner of the food delivery has implications: that "breastfed infants self-regulate intake volume", whereas bottle-fed infants receiving expressed breast milk or formula have "increased bottle emptying, poorer self-regulation, and excessive weight gain in late infancy", and that such early practice of self-regulation correlate with adult patterns of weight gain (ibid.). The AAP policy notes that "[m]edical contraindications to breastfeeding are rare". The transmission of some viral diseases through breastfeeding is reportedly preventable, e.g., by expressing breast milk and subjecting it to Holder pasteurization.
== Biosynthesis == Epothilone B is a 16-membered polyketide macrolactone with a methylthiazole group connected to the macrocycle by an olefinic bond. The polyketide backbone was synthesized by type I polyketide synthase (PKS) and the thiazole ring was derived from a cysteine incorporated by a nonribosomal peptide synthetase (NRPS). In this biosynthesis, both PKS and NRPS use carrier proteins, which have been post-translationally modified by phosphopantetheine groups, to join the growing chain. PKS uses coenzyme-A thioester to catalyze the reaction and modify the substrates by selectively reducing the β carbonyl to the hydroxyl (Ketoreductase, KR), the alkene (Dehydratase, DH), and the alkane (Enoyl Reductase, ER). PKS-I can also methylate the α carbon of the substrate. NRPS, on the other hand, uses amino acids activated on the enzyme as aminoacyl adenylates. Unlike PKS, epimerization, N-methylation, and heterocycle formation occurs in the NRPS enzyme.
TC# 2.A.3 - Amino Acid-Polyamine-Organocation (APC) Superfamily TC# 2.A.18 - Amino Acid/Auxin Permease (AAAP) Family TC# 2.A.23 - Dicarboxylate/Amino Acid:Cation (Na+ or H+) Symporter (DAACS) Family TC# 2.A.26 - Branched Chain Amino Acid:Cation Symporter (LIVCS) Family TC# 2.A.42 - Hydroxy/Aromatic Amino Acid Permease (HAAAP) Family TC# 2.A.78 - Branched Chain Amino Acid Exporter (LIV-E) Family TC# 2.A.95 - 6TMS Neutral Amino Acid Transporter (NAAT) Family TC# 2.A.118 - Basic Amino Acid Antiporter (ArcD) Family TC# 2.A.120 - Putative Amino Acid Permease (PAAP) Family
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.